It is essential that criteria for determining menopause are defined in patients with luminal breast cancer because, bearing in mind the mechanism of action of aromatase inhibitors (AIs), only patients that meet strict post-menopausal criteria will be candidates to receive these agents, in both early and metastatic disease [28]. This evidence concerns the gene CYP19A1 and metastatic neoplasm.